EXPAREL 266 mg
402-C-322
Phase 3 small_molecule completed
Quick answer
EXPAREL 266 mg for Posterolateral Thoracotomy is a Phase 3 program (small_molecule) at Pacira BioSciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pacira BioSciences
- Indication
- Posterolateral Thoracotomy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed